All In Biotech

Drug Trial Radar · NCT05395533

A Phase 1 Study of TRS005 in Patients With R/R CD20-positive B-NHL.

A Multicenter, Single-arm, Dose-escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Effectiveness of TRS005 in Patients With Relapsed or Refractory CD20-positive B-NHL

Last checked: Nov 19, 2026Latest source record: Jun 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

147

Actual

Start

Sep 8, 2020

Primary completion

Jul 31, 2025

Study completion Dec 31, 2025

Sponsor

Sponsor type
Industry
First posted
May 27, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is a multicenter, open, single arm, dose increasing and extended clinical trial. The dose was increased according to the "3 + 3" rule. Patients with recurrent or refractory CD20 positive B-cell non-Hodgkin's lymphoma were selected to evaluate the safety, tolerance (DLT, MTD) and pharmacokinetic (PK) characteristics of TRS005 by intravenous drip.

Conditions

  • CD20-positive B-cell Non-Hodgkin Lymphoma

Interventions

  • Recombinant CD20 monoclonal antibody-MMAE conjugte for injectionDrug

    The dose of the enrolled subjects was increased according to the following 6 dose groups: 0.1mg/kg, 0.5mg/kg, 1.0mg/kg, 1.5mg/kg, 1.8mg/kg, and 2.1mg/kg.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Dose-limiting ToxicityTime frame: Cycle 1(Days 1-21)
  2. MTD,Maximum Tolerated DoseTime frame: Cycle 1(Days 1-21)
  3. Number of Participants With Treatment-emergent Adverse Event (TEAE)Time frame: Baseline up to approximately 5 years

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Chinese Academy of Medical Sciences, Cancer Hospital

    Beijing, Beijing Municipality, China

  • Sun Yat-sen University Cancer Center (SYSUCC)

    Guangzhou, Guangdong, China

  • Henan Cancer Hospital (Affiliated Cancer Hospital of Zhengzhou University)

    Zhengzhou, Henan, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China

  • Second Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China

  • Tianjin Medical University Cancer Institute & Hospital (TMUCIH)

    Tianjin, Tianjin Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.